$CBIS COLORADO SPRINGS, CO--(Marketwired - Apr 6, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today acknowledges and is very excited about the Landmark move with the Drug Enforcement Agency's (DEA) decision to review marijuana's federal drug classification as early as mid-2016. Rescheduling marijuana would ease restrictions on research across the country, while at the same time reducing penalties for marijuana offenses. Increased research capabilities could spur innovation and growth in the cannabis industry.

To review the Huffington Post article please click here to read the article in its entirety.

http://tinyurl.com/hsgbykw